FDA clears Cadence pain drug for review

Cadence Pharmaceuticals' stock shot up on the FDA announcement that the company does not have to conduct any additional studies of Acetavance, an intravenous version of acetaminophen. Cadence expects to submit an NDA in the second quarter of 2009. Release

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."